ArticleClinical epigenetics2025
Genome-wide DNA methylation profiles of colorectal tumors in Lynch syndrome and familial adenomatous polyposis.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting the Epigenome in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Lynch Syndrome as a Spectrum of Four Distinct Genetic Disorders: Toward Genotype-Guided Precision Management in the NGS Era.Cancers · 2026Review
- Advances in research on congenital and hereditary intestinal diseases: From molecular mechanisms to precision medicine.Intractable & rare diseases research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLynch syndrome (LS) and familial adenomatous polyposis (FAP) are hereditary cancer predisposing syndromes characterized by increased risk of especially early-onset colorectal cancer. Predisposition to LS is caused by germline mutations in DNA mismatch repair genes leading to elevated cancer progression and microsatellite instability. FAP is associated with germline mutations in APC promoting cancer initiation and chromosomal instability. DNA methylation is an important epigenetic mechanism in early tumorigenesis via, e.g., field defects in non-neoplastic colon. Our aim was to study genome-wide methylation changes in colorectal specimens (adenomas and carcinomas supplemented with paired normal colon) obtained during colonoscopy surveillance, and explore the role of such alterations in tumorigenesis, with a special focus on early changes. To our best knowledge, this study is the first one to compare altered DNA methylation genome-wide in LS and FAP-associated colorectal neoplasia.
resultsDNA methylation alterations were subtle in FAP adenomas, whereas in LS adenomas, changes were abundant when compared to their normal counterparts. When FAP normal and LS normal colon were compared, DNA methylation changes of FAP normal colon mirrored those occurring in LS tumors, suggesting that colorectal tumorigenesis-associated DNA methylation alterations take place already in FAP normal colon mucosa. DNA methylation age was more variable in LS than FAP normal colon, and in proximal than distal colon, when compared to individuals' age at the time of sampling. In LS tumors, DNA methylation changes (hyper- and hypomethylation) were abundant even in adenomas with low-grade dysplasia and stable microsatellites and peaked in adenomas with high-grade dysplasia. LINE-1 hypomethylation was more prominent in LS adenomas than FAP adenomas, but normal colon of LS and FAP displayed similar levels of LINE-1 methylation.
conclusionsGenome-wide DNA methylation changes are an integral part of FAP and LS-associated colorectal tumorigenesis. Occurrence at early stages, even in non-neoplastic colonic mucosa, and increased prevalence with progressive dysplasia suggest a role in tumor development. Overlap of many of the topmost DNA methylation alterations between LS and FAP, and previous reports of their occurrence in sporadic colorectal and other tumors as well, imply their broad biological relevance and possible biomarker potential for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.